466 related articles for article (PubMed ID: 27305860)
1. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
[TBL] [Abstract][Full Text] [Related]
3. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
4. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis.
Santilli F; Vazzana N; Iodice P; Lattanzio S; Liani R; Bellomo RG; Lessiani G; Perego F; Saggini R; Davì G
Thromb Haemost; 2013 Dec; 110(6):1232-40. PubMed ID: 24030807
[TBL] [Abstract][Full Text] [Related]
5. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.
Danese S; Katz JA; Saibeni S; Papa A; Gasbarrini A; Vecchi M; Fiocchi C
Gut; 2003 Oct; 52(10):1435-41. PubMed ID: 12970136
[TBL] [Abstract][Full Text] [Related]
6. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration.
Davì G; Chiarelli F; Santilli F; Pomilio M; Vigneri S; Falco A; Basili S; Ciabattoni G; Patrono C
Circulation; 2003 Jul; 107(25):3199-203. PubMed ID: 12810609
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
8. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
[TBL] [Abstract][Full Text] [Related]
9. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
11. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress.
Ferrante E; Vazzana N; Santilli F; Di Cicco M; Lauriti C; Di Battista L; Ciabattoni G; Di Matteo L; Davì G
Free Radic Biol Med; 2010 Sep; 49(5):857-64. PubMed ID: 20541603
[TBL] [Abstract][Full Text] [Related]
12. Determinants of platelet activation in human essential hypertension.
Minuz P; Patrignani P; Gaino S; Seta F; Capone ML; Tacconelli S; Degan M; Faccini G; Fornasiero A; Talamini G; Tommasoli R; Arosio E; Santonastaso CL; Lechi A; Patrono C
Hypertension; 2004 Jan; 43(1):64-70. PubMed ID: 14656953
[TBL] [Abstract][Full Text] [Related]
13. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
14. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
15. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
16. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
[TBL] [Abstract][Full Text] [Related]
17. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G
Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating platelet derived microparticles in Crohn's disease patients.
Tziatzios G; Polymeros D; Spathis A; Triantafyllou M; Gkolfakis P; Karakitsos P; Dimitriadis G; Triantafyllou K
Scand J Gastroenterol; 2016 Oct; 51(10):1184-92. PubMed ID: 27191369
[TBL] [Abstract][Full Text] [Related]
19. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
